- Trial Phase
- Phase 2 (potentially pivotal)
- Time to Market
- BLA filing targeted H1 2027; potential US launch in early 2028 if approved
- Why 6/10
- The next hard binary catalyst is the Phase 2 AQUAx2 (NCT05926765) pivotal topline data readout, originally guided for late 2026 (though some sources now point to 2027). This placebo-controlled, registrational study is the primary value driver for AAV2-hAQP1. The $50M Oberland Capital tranche is explicitly tied to positive Phase 2 data, underscoring its importance. score=6 because the readout is a dated binary catalyst within ~6-12 months on the company's lead pipeline asset, though MeiraGTx has other late-stage programs (AAV-GAD, bota-vec).
Watch for the Phase 2 AQUAx2 topline readout, expected late 2026 or early 2027 — positive data unlocks a $50M tranche from Oberland Capital and enables BLA filing in H1 2027. The stock already trades near 52-week highs with a Strong Buy analyst consensus; the readout is the next major inflection point.
Price Chart
Executive Summary
AAV2-hAQP1 is MeiraGTx's lead gene therapy program for radiation-induced xerostomia (chronic dry mouth), a condition affecting over 170,000 patients in the US with no FDA-approved therapies. Phase 1 data showed durable 3-year safety and efficacy from a single administration. The drug has received both FDA Breakthrough Therapy and RMAT designations. The Phase 2 AQUAx2 pivotal trial readout (late 2026/early 2027) is the key catalyst, supported by a recent $400M Oberland Capital financing that includes $50M tied to positive Phase 2 data. With a strong analyst consensus (13 Buy-equivalent ratings, 1 Hold, mean PT $28.25) and de-risked regulatory path, the drug represents a potentially first-in-class treatment for a large unmet need.
How It Works
Radiation therapy for head and neck cancer damages the salivary glands' water-secreting cells, causing chronic dry mouth. AAV2-hAQP1 is a one-time gene therapy delivered directly into the parotid (saliva) gland via a thin tube inserted through the duct opening in the mouth. It uses a harmless AAV2 virus shell to deliver a working copy of the human aquaporin-1 (hAQP1) gene, which encodes a water-channel protein. Once inside the damaged gland cells, the gene makes the cells permeable to water again, allowing saliva to flow into the mouth.
Trial Status
Phase 1 AQUAx study (n=24) completed with positive 3-year durability data reported April 16, 2026 showing sustained saliva flow and symptom improvement from a single dose. Phase 2 AQUAx2 (NCT05926765) is a randomized, double-blind, placebo-controlled, potentially pivotal trial enrolling ~276 patients across the US, Canada, and UK. Enrollment of final high-dose cohorts was targeted for Q4 2025 completion.
The Two-Sided Case
Upcoming Catalysts
- Phase 2 AQUAx2 pivotal topline data readout — expected late 2026 or 2027
- $50M milestone payment from Oberland Capital triggered by positive Phase 2 AQUAx2 data
- Potential BLA submission to FDA in H1 2027 (targeting early 2028 US launch)
- Possible expansion of AAV2-hAQP1 into Sjögren's syndrome-related xerostomia (preclinical stage)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
MeiraGTx Holdings plc 8-K MGTX ·Originating report